All In Biotech

Free tool

FAERS Monitor: Esomeprazole Strontium

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202342 or its brand name (Esomeprazole Strontium, Esomeprazole Strontium). Reports on generic versions are filed under their own applications.

Reports

19

Serious

11

58% of reports

Hospitalization

5

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3
  • diarrhoea3
  • fatigue3
  • abdominal pain2
  • asthenia2
  • constipation2
  • cyst2
  • dehydration2
  • faecal volume increased2
  • faecaloma2
  • functional gastrointestinal disorder2
  • intestinal obstruction2
  • memory impairment2
  • off label use2
  • white blood cell count decreased2

Reports by year received

View as table
YearReports
20131
20154
20171
20181
20191
20201
20213
20223
20231
20241
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,140 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
faecal volume increased24278.41150.04,792
functional gastrointestinal disorder2640.9172.7718
faecaloma2404.2108.9452
cyst2178.448.1198
intestinal obstruction258.715.863
white blood cell count decreased220.45.520
dehydration216.64.516
memory impairment216.14.315
constipation210.22.79
abdominal pain29.52.68
asthenia25.91.64
diarrhoeaSignal35.11.87
fatigueSignal34.31.55
death33.91.44
off label use22.50.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.